Neurite plasticity is a critical aspect of brain functional recovery after stroke. Emerging data suggest that Ras-related C3 botulinum toxin substrate 1 (Rac1) plays a central role in axonal regeneration in the injured brain, specifically by stimulating neuronal intrinsic growth and counteracting the growth inhibitory signaling that leads to growth cone collapse. Therefore, we investigated the functional role of Rac1 in axonal regeneration after stroke.
Introduction
Stroke is the primary cause of adult long-term disability in both the USA and worldwide [1] . Although the mortality rate of stroke is decreasing, the incidence of stroke is rising, which translates into an increasing prevalence of patients living with persistent disability [2] . Mounting evidence suggests that axonal outgrowth is a critical aspect of functional recovery because it is essential for establishing new neural connections to compensate for the stroke-induced loss of function. Thus, targeting this process has emerged as an alternative and potentially more tractable target to reduce long-term disability after stroke [3] . However, after injury, this axonal regrowth and remodeling in the adult mammalian central nervous system (CNS) is limited, partially because there is a lack of robust activation of intrinsic neuronal properties for outgrowth, but also because the extrinsic glial environment, such as glial scar formation, inhibits axonal regeneration.
Ras-related C3 botulinum toxin substrate 1 (Rac1) is a Rho-related small GTPase that plays a critical role in axonal growth during neuronal development [4] . Rac1 is ubiquitously expressed throughout the brain [5] . However, Rac1 becomes inactivated when bound to guanosine diphosphate (GDP) and activated when bound to guanosine triphosphate (GTP). Interestingly, emerging data suggest a critical role of the Rac1 pathway in axonal regeneration in the injured brain, but no studies have investigated whether Rac1 is a viable target for axonal regeneration after cerebral ischemia.
Downstream substrates of Rac1 (ERK1/2, GFAP, i.e.) are implicated in the stimulation of neuronal intrinsic outgrowth properties, as well as counteracting the glial extrinsic environment, which represent the two critical components that govern axonal plasticity in injured brain. In cultured mouse cortical neurons, Rac1 is required for atorvastatin-induced neurite plasticity after glutamate-induced neuronal excitotoxicity [6] . Interestingly, Rac1 levels are increased in peri-infarct regions in rats after stroke, and this elevation persists for 2 weeks after stroke during the critical phase of axonal regeneration and recovery [7] . Therefore, we investigated the functional role of Rac1 in axonal regeneration and its mechanisms in the recovery phase after stroke in mice.
Methods

Animals
The study was approved by the Center for Laboratory Animal Care of the University of Connecticut Health Center and University of Texas Health Science Center, and performed following the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The C57BL/6J WT male mice (7-8 weeks) were from Charles River.
Middle Cerebral Artery Occlusion (MCAO)
MCAO procedure has been described in details previously [8, 9] . Briefly, after a skin incision along the midline of the mouse neck, 90-min MCA occlusion was induced in mice using an intraluminal filament. After occlusion, mice were reperfused by suture withdrawal and then sacrificed 14 or 28 days later. Mice of the sham groups underwent the same procedure as those in the stroke groups, but without occluding the MCA.
Histological Assessment
Brain atrophy measurement was analyzed as previously described [9, 10] . Generally, mice were perfused and fixed with 4% paraformaldehyde 28 days after stroke. The fixed brains were then sliced for cresyl violet staining in accordance with previously published procedures [10, 11] . The brain tissue loss was determined following this calculation: % brain tissue lost = 100% × [(contralateral hemisphere area − contralateral ventricular area) − (ipsilateral hemisphere area − ipsilateral ventricular area)]/(contralateral hemisphere area − contralateral ventricular area).
Production of Lentiviral Vector
Lentiviral vectors carrying Rac1 and GFP were generated following the procedures described in our previous publications [12] . The concentrations of the lentivirus were 10 9 transducing units/mL, which was titered by transducing 293FT cells and counting eGFP-positive colonies [12] . For virus titering, briefly, 293FT cells were cultured on a 24-well plate and lentivirus were added to wells. The eGFP fluorescence was visualized under a fluorescent microscope after incubation. To determine the titer of lentivirus, the overall fraction of cells that were eGFP positive in each well was calculated, multiplied by the corresponding total cell number in each well, then divided by the actual volume of added lentivirus.
Lentivirus Administration In Vivo
Lentiviral vectors encoding Rac1 or GFP were injected into the mouse brains following previously established methods [12] . Briefly, a four-point injection was carried out at the following coordinates: 0.5 mm anterior to the bregma, 2.0 or 3.0 mm lateral (right) to the sagittal suture, and 1.0 or 2.8 mm from the surface of the skull [12] . A total of 1 μL of concentrated lentivirus (10 9 transducing units/mL) was injected into each position at a rate of 0.5 μL/min with a 30-gauge needle on a 10-μL Hamilton syringe (catalog no. 80010). After the lentivirus was injected, the needle remained in position for 10 min before it was withdrawn. This injection protocol causes minimal damage to the brain tissue according to our previous experience and is accounted for by control groups injected with GFP virus [12] .
Drug Administration In Vivo and In Vitro
For in vivo studies, Rac1 inhibitor, NSC23766 (NSC), was administrated daily from days 7 to 13 after stroke (7 days, 4.0 mg/kg, i.p.). Control mice received the equal amount of vehicle. While most of the published work used 2.5 mg/kg/ day in mice [13, 14] , we chose 4.0 mg/kg/day to ensure an effective inhibition and found no evidence for toxicity at this dose. For in vitro experiments, the concentration of 30 μM NSC was used [15] . BrdU (bromodeoxyuridine) was injected 7 days after stroke (dose, 50 mg/kg, i.p./8 h for 24 h) [16] .
Behavior Measurements Using Pellet Reaching Test
Pellet reaching is a well-organized movement involving complex neural control systems. This test has the capability to measure both the motor and sensory functions of the impaired limb and is increasingly used in long-term survival studies for stroke recovery [17] [18] [19] . As previously described, the success rate of pellet reaching was calculated according to the following equation (number of successful reaches/total number of reaches × 100). Mice were pre-tested to assess and control for individual differences. All studies were conducted and analyzed by blinded investigators.
Oxygen-Glucose Deprivation (OGD) in Primary Cortical Neurons and Astrocytes
To assess the role of Rac1 in the intrinsic capacity of neurons for axonal outgrowth, we used mouse primary neuronal culture system, where there is no/minimal glial influence. To measure outgrowth, we utilized a microfluidic chamber which separates axons from neuronal soma and permits direct axonal outgrowth monitoring in cortical neurons [20] . Cortical neurons were challenged by OGD for 2 h [21] . Twenty-four hours after OGD, the cells were co-cultured with 30 μM NSC until 96 h after OGD. Axonal elongation and numbers were then analyzed by NFL staining at 96 h after OGD, as others have shown significant axonal regeneration induced by OGD at this time point [20] . Elongating axons were imaged with a fluorescence microscope. The number of axons were counted and the length of each axon was measured by manually tracing each individual axon with ImageJ software. Primary astrocytes were challenged by OGD for 2 h. Twenty-four hours after OGD, the cells were co-cultured with 30 μM NSC until 96 h after OGD.
Western Blot Analysis
Western blot procedures were performed as previously described [1, 23] . For in vivo studies, GFAP, p-LIMK 1, p-ERK1/2, and p-MEK1/2 were analyzed in the brain samples harvested 14 days after stroke. Rac1 in mouse brain was detected 7 days after injection of Rac1 or GFP vectors. For in vitro experiments, glial fibrillary acid protein (GFAP) expression in primary astrocytes after OGD was probed. β-Actin or β-tubulin was employed as a loading control. The integrated optical density (IOD) of each band was measured using ImageJ. The IOD results were normalized by dividing each value by the mean IOD of the control groups.
Immunohistochemistry and Data Quantification
The staining method was described in previous publications [1, 22] . The Neurofilament-L (NFL) and GFAP were stained in mouse brain slices 28 days after stroke. After staining, the images were recorded and analyzed using a Zeiss Axiovert 200M microscope (Carl Zeiss, Oberkochen, Germany) with an X-Cite 120Q fluorescence illumination system (Lumen Dynamics Group Inc., Mississauga, ON, Canada) and Zeiss image acquisition software (Zeiss LSM 510). Identical digital imaging acquisition parameters were used throughout t he study. NFL or GFAP were semi-quantified as the integrated optical density (IOD) of green-positive signals in the penumbra of the ischemic hemisphere using ImageJ. The IOD results were normalized by dividing each value by the mean IOD of the control groups.
Statistical Analyses
Data are presented as the mean ± standard error of the mean (SEM). Mean comparisons between the experimental groups were analyzed by one-way or two-way analysis of variance (ANOVA) followed by post hoc tests for multiple comparisons when appropriate. P < 0.05 was considered statistically significant by using SPSS 19 software (Chicago, IL, USA). Both behavioral and histological assessments were performed by an investigator blinded to the vectors/drug treatment.
Results
Delayed Inhibition of Rac1 Led to Poorer Functional Recovery and Reduced Axonal Density
A specific Rac1 inhibitor, NSC23766 (NSC), or vehicle (saline) was administrated to WT mice starting 7 days after MCAO and injected once daily for 7 days (4.0 mg/kg/day). We tested functional motor deficits at 28 days after stroke onset by performing the pellet reaching test. Stroke produced consistent deficits in the pellet reaching test, and gradual recovery was observed in vehicle-treated stroke mice. We found that the delayed inhibition of Rac1 with NSC significantly worsened functional recovery from day 14 to day 28 after stroke (day 28, vehicle 0.39 ± 0.03 vs. NSC 0.18 ± 0.03, n = 7-9, *p < 0.05; Fig. 1a) .
We then studied the effect of delayed Rac1 inhibition in axonal density in the peri-infarct zone. We found that Rac1 inhibitor treatment significantly reduced axonal density (neurofilament staining, NFL) in the peri-infarct zone, assessed at 28 days after stroke (vehicle 1.00 ± 0.12 vs. NSC 0.50 ± 0.04, n = 4, *p < 0.05; Fig. 1b ).
Delayed Rac1 Inhibition Did Not Increase Tissue Loss or Reduce the Number of BrdU-Positive Cells
It remains possible that Rac1 inhibition affects brain injury, which would contribute to the changes in functional outcome and axonal density seen in our experiments. The likelihood is slim as NSC was started at 7 days after stroke, when the infarct growth is complete. Regardless, we performed CV staining at 28 days after stroke to examine infarction (cavity size). No differences (vehicle 34.2 ± 4.3% vs. NSC 31.26 ± 3.4%, n = 7-9/group, p > 0.05; Fig. 1c, e) were seen between vehicle and NSC-treated groups. Rac1 has been implicated in neurogenesis, which could potentially contribute to changes in axonal density. To measure neurogenesis, we injected BrdU to label proliferating cells in the brain 7 days after stroke and stained for BrdU-positive cells 28 days after stroke. No difference in BrdU staining in the peri-infarct zone was observed between the vehicle-treated and NSC-treated groups (vehicle 1.00 ± 0.37 vs. NSC 1.00 ± 0.18, n = 4, p > 0.05; Fig. 1d ).
Delayed Overexpression of Rac1 Improved Functional Recovery and Increased Axonal Density after Stroke
We next studied how Rac1 affects stroke recovery by overexpressing Rac1 using a lentiviral vector carrying the Rac1 gene.
We injected highly concentrated lentivirus encoding WT Rac1 at 7 days after stroke into both the cortex and striatum. We found that delayed overexpression of Rac1 improved functional recovery, as assessed by the pellet reaching test from day 14 to day 28 after stroke (day 28, LV-GFP 0.34 ± 0.02 vs. LV-Rac1 0.51 ± 0.04, n = 8, *p < 0.05; Fig. 2a) . Axonal density was also significantly increased in the peri-infarct zone in the group with Rac1 overexpression (data LV-GFP 1.00 ± 0.08 vs. LV-Rac1 1.67 ± 0.10, *p < 0.05, n = 4, Fig. 2b) .
The in vivo effect of the lentivirus on protein expression was confirmed by western blot. To assess this, vectors were Fig. 1 Delayed inhibition of Rac1 led to poorer recovery and reduced axonal density after stroke. a Functional recovery assessed by pellet reaching test from day 14 to day 28 after stroke. N = 7-9, *p < 0.05. b Axonal density (neurofilament staining) in the peri-infarct zone was assessed on 28 days after stroke. Scale bars: 10 μm. N = 4, *
)]/ (contralateral hemisphere area − contralateral ventricular area). Red area: ipsilateral hemisphere area; yellow area: ipsilateral ventricular area; purple area: contralateral hemisphere area; blue area: contralateral ventricular area. A specific Rac1 inhibitor, NSC23766 (NSC), or vehicle (saline) was administrated to WT mice starting 7 days after MCAO and injected once daily for 7 days (4.0 mg/kg/day). Data were as mean ± SEM injected into both the cortex and striatum in mice at 7 days after stroke. One week after the injection, western blot analysis demonstrated a consistent increase in levels of Rac1 protein in the stroke hemisphere (LV-GFP 1.00 ± 0.11 vs. LVRac1 1.53 ± 0.11, n = 4, *p < 0.05; Fig. 2c ).
Rac1 Inhibition Reduced P-LIMK 1, P-MEK1/2, and P-ERK1/2 In Vivo
We then moved on to study the mechanisms of Rac1 in stimulating axonal regeneration after stroke. MEK1/2 and ERK1/2 are well-known pro-regenerative molecules, as they stimulate the expression of pro-regenerative genes. Importantly, Rac1 is known to activate MEK (via PAK1), which then phosphorylates ERK. Additionally, Rac1 also targets LIMK1, another potent enhancer of axonal plasticity [22] [23] [24] . As expected, we found that delayed inhibition of Rac1 reduced the levels of p-LIMK 1 (day 14, vehicle 1.47 ± 0.09 vs. NSC 0.75 ± 0.12, n = 4, 
Inhibition of Rac1 Reduced Axonal Length and Number after OGD
We then examined the effect of Rac1 inhibitor (NSC) on axonal outgrowth by using a microfluidic chamber to separate axons from neuronal soma. At 6 days in vitro, cortical neurons were challenged by OGD for 2 h and then co-cultured with Fig. 2 Overexpression of Rac1 improved functional recovery and increased axonal density after stroke. a Functional recovery assessed by pellet reaching test from day 14 to day 28 after stroke. N = 8, *p < 0.05. b Axonal density (neurofilament staining) in the peri-infarct zone was assessed on 28 days after stroke. Scale bars: 10 μm. N = 4, *p < 0.05. c Rac1 lentivector significantly increased Rac1 protein levels 7 days after injection in vivo. N = 4, *p < 0.05. We injected highly concentrated lentivirus encoding WT Rac1 1 week after stroke into both the cortex and striatum. Data were as mean ± SEM At this dosing regimen, NSC incubation had no effect on cortical neuron's cell viability in vitro (OGD + vehicle 60.3 ± 2.8% vs. OGD + NSC 58.92 ± 3.2%, p > 0.05; Fig. 4c ).
Inhibition of Rac1 Increased GFAP after Stroke In Vivo and in Primary Astrocytes after OGD
We hypothesized that Rac1 also enhances axonal regeneration by counteracting the growth inhibitory signaling (e.g., glial scar) that leads to growth cone collapse, providing an additional mechanism for improved functional recovery after stroke. Our data showed that GFAP, a marker for glial scar formation and a signal of axonal growth inhibition, had elevated expression in the ischemic hemisphere at 28 days after stroke (Fig. 5a) . Furthermore, we observed that the Rac1 inhibitor treated cohort had upregulated levels of GFAP at 14 days after stroke (day 14, vehicle 1.00 ± 0.24 vs. NSC 1.66 ± 0.11, n = 4, *p < 0.05; Fig. 5b) .
Finally, we then confirmed the effects of Rac1 on GFAP in primary astrocytes after OGD. In line with the in vivo data, we demonstrated that inhibition of Rac1 increased the level of GFAP in astrocytes at 96 h after OGD (vehicle 1.45 ± 0.06 vs. NSC 2.22 ± 0.15, n = 4, # p < 0.05; Fig. 5c ).
Discussion
In the present study, we demonstrated that Rac1 plays vital roles in brain plasticity and functional recovery after experimental stroke. Specifically, we have made the following significant findings: (1) Rac1 inhibition led to poorer functional recovery after stroke in long-term survival and reduced axonal density in the penumbra. This treatment did not cause changes in either the brain cavity size or the number of newly divided cells, suggesting that outgrowth of existing neurons is the major contributor to changes in axonal density following treatment. (2) Overexpression of Rac1 promoted improvement of motor and sensory functions, increased long-term survival, and also increased axonal density. (3) Rac1 inhibition reduced the activation of pro-regenerative molecules such as ERK and MEK. (4) Treatment with Rac1 inhibitor exacerbated GFAP expression in vivo and in vitro after stroke, potentially also contributing to reduced axonal outgrowth.
The weak intrinsic growth capacity in neurons and the inhibitory factors from extrinsic glial environments are among the major causes of regenerative failure in the CNS after injury [25, 26] . Rac1 promotes axonal regeneration by counteracting the glial inhibitory signal to axon growth. Rac1 signaling can reduce glial scar formation, a major physical and chemical barrier for axonal growth following stroke [27] . Mounting evidence shows that glial inhibitory signals are the major cause of growth cone collapse and limited CNS axonal regeneration. Reactive astrocytes are the primary contributors of the formation of glial scar, which is a major physical and chemical barrier for axonal outgrowth following injury. Chondroitin sulfate proteoglycans (CSPGs), secreted by the astrocytic scar, are highly inhibitory to regeneration after stroke, and Fig. 4 Inhibition of Rac1 reduced axonal length and numbers after OGD. Microfluidic chamber was used to separate axons from neuronal soma. At 6 days in vitro, cortical neurons co-cultured with 30 μM NSC23766 for 96 h after challenged by OGD for 2 h, axonal length (a) and number (b) were analyzed by immunocytochemistry NFL staining. N = 4, *p < 0.05. Scale bars: 50 μm. c NSC incubation had no effect on cortical neuron's cell viability. N = 4, p > 0.05. Data were presented as mean ± SEM decreased CSPG contributes to improved plasticity in stroke. Secreted CSPG inhibits axonal growth by binding specific receptors expressed on the growth cone membrane, causing the cone to collapse and ultimately leading to axonal retraction. In spinal cord injury models, animals treated with constitutively active Rac1 showed significantly lower expression of GFAP and CSPGs than untreated controls [28] . In line with this report, our study demonstrated that Rac1 inhibition exacerbated GFAP signaling in the brain after stroke using both in vivo and in vitro models.
Our work additionally showed that Rac1 stimulates the intrinsic capacity of neurons for axonal outgrowth. Rac1 upregulates the extracellular signal-regulated kinase (ERK) pathway, which is well known to induce axonal regeneration in the injured central nervous system [29, 30] . This pathway consists of three kinases: rapidly accelerated fibrosarcoma (Raf), mitogen-activated protein/extracellular signalregulated kinase (MEK), and ERK. Pak1, the downstream target of Rac1, phosphorylates Raf, which then phosphorylates MEK, which in turn phosphorylates ERK [29] . Importantly, ERK1/2 mediates the transcriptional activation of regeneration-associated genes (RAGS). This can occur either directly, when phosphorylated ERK1/2 (p-ERK1/2) translocates from the cytoplasm to the nucleus, or indirectly, when p-ERK1/2 phosphorylates downstream kinases in the cytoplasm which subsequently enter the nucleus [31, 32] . For example, ERK phosphorylates cyclic adenosine monophosphate response element binding protein (CREB). When phosphorylated, CREB induces the transcription of genes important for axonal plasticity processes after CNS injury, such as growth-associated protein 43 (GAP43) [26] . Our work suggests that Rac1 and MEK/ERK interact with each other, although a causative relationship needs to be investigated in the future.
ERK1/2 activation in neurons stimulates pro-regenerative gene expression. However, activation of ERK1/2 in astrocytes may also stimulate gliosis, which would paradoxically hinder axonal regeneration. This effect could be minimal in stroke, as our IHC showed p-ERK1/2 was mostly confined to neuronal cells at 28 days after stroke (data not shown), indicating that ERK1/2 signaling is selectively activated in neurons during the chronic phase of stroke.
Interestingly, the literature shows that Rac1 is proregenerative after brain injury; however, other studies have shown that Rac1 inhibition may also provide neuroprotection and reduce injury in the acute phase of injury [33] . To minimize potential effects on acute injury size, we deliberately started Rac1 intervention (both Rac1 inhibitor and lentiviral overexpression) at 7 days after the onset of stroke. This allowed us to hone in on studying the role of Rac1 in brain plasticity. In general, 7 days post-stroke is beyond the window for neuronal protection in this model, as stroke infarction completes within a week after MCA occlusion [34] .
One caveat of this study is that axonal regeneration is influenced by factors that can be produced by the peripheral system, such as IL-1 and TGF-beta, as these cytokines affect glial scar formation [35] . Rac1 is also an important mediator of immunity, and inhibition of Rac1 in peripheral blood mononuclear cells from human blood was shown to reduce IL-1 beta release [36] . Although manipulation of Rac1 provides considerable evidence for a combined effect of both central and peripheral responses, brain injection of lentivirus may not allow us to observe peripheral effects. We will closely monitor changes in cytokines using peripheral blood samples. This approach will also help to evaluate the possible role of Rac1 in post-stroke inflammation, as Rac1 is known to participate in the immune response [37, 38] .
The translational significance of our findings is high, as we identified a molecule that plays critical roles in enhancing brain plasticity and functional recovery after stroke. Our experiments significantly improved our understanding of the complex axonal growth program that is activated after stroke. Given that the economic burden of post-stroke disability will continue to increase as the population ages and acute stroke care improves, developing novel drugs to improve functional recovery is a growing and urgent public health need. Currently, the only pharmacological treatment for stroke is tissue plasminogen activator (tPA) [2] , which has a short therapeutic window, leaving no effective treatment available for the majority of stroke patients. A weak intrinsic regenerative potential in neurons and inhibition from glial cells are major causes of limited axonal regeneration after stroke. Here, we identified a target molecule that stimulates intrinsic components of neuronal growth capacity and simultaneously reduces glial inhibition. Therefore, targeting this molecule may offer robust improvements in functional recovery after stroke. It is especially important in the elderly, the population at greatest risk of stroke, as we have shown an increased astrogliosis occurs in aged individuals after stroke, which is associated with worse recovery in animal models [11] .
In summary, we newly demonstrated a critical role of Rac1 in promoting axonal regeneration and brain remodeling after experimental stroke. Our work suggests that Rac1 targets the two key components in axonal rewiring in the post-ischemic brain, both by enhancing the intrinsic properties of neurons to extend axons, as well as by inhibiting glial scar formation in the chronic recovery phase after experimental stroke. Our study suggests that Rac1 signaling is a potential therapeutic target for promoting brain remapping and functional recovery after stroke.
